Since we used low doses of both JNKi and TRAIL in our orthotophic pancreatic model - up to 40 fold lower than prior glioma model [37] [27] - further studies should evaluate if an increase in dosage or duration of treatment would be beneficial in highly resistant tumors, especially in patient-derived xenograft model systems. This evidence concerns the gene TNFSF10 and central nervous system cancer.